Tuberculosis vaccine research: the impact of immunology

Current Opinion in Immunology

Volumn 21, Issue 3, 2009, Pages 331-338

  Barker, Lewellys F ^a   Brennan, Michael J ^a   Rosenstein, Peri K ^a   Sadoff, Jerald C ^a  

^a Aeras Global TB Vaccine Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AERAS 402; AERAS 402 VACCINE; AERAS 404; AERAS 404 VACCINE; AERAS 485; AERAS 485 VACCINE; BCG 30; BCG 30 VACCINE; BCG VACCINE; CRUCELL AD35 VACCINE; CYTOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; GSK M 72; GSK M 72 VACCINE; HYBRID 1 VACCINE; HYBRID PROTEIN; HYVAC 4; IMMUNOLOGICAL ADJUVANT; LISTERIOLYSIN; MVA 85A VACCINE; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM VACCINE; PERFRINGOLYSIN; RECOMBINANT BCG VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VFM X VACCINE;

ANTIGEN DETECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTION; REGULATORY T LYMPHOCYTE; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINE PRODUCTION;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 67049145538     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.05.017     Document Type: Review

References (71)

1. World Health Organization. WHO Report 2009: Global Tuberculosis Control-Epidemiology, Strategy, Financing (2009), WHO, Geneva
2. Lawn S.D., Bekker L.G., Middelkoop K., Myer L., and Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 42 (2006) 1040-1047
3. Williams B.G., and Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301 (2003) 1535-1537
4. Bruns H., Meinken C., Schauenberg P., Harter G., Kern P., Modlin R.L., Antoni C., and Stenger S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119 (2009) 1167-1177
5. Cooper A.M., and Khader S.A. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 226 (2008) 191-204. This review illustrates the complex role of multiple IL-12-related cytokines in the cell-mediated immune response that attempts to control Mtb in the lung. Description of the protective or detrimental roles of IL-17 and IL-23, depending on timing of action, is quite relevant to vaccine research.
6. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
7. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
8. Kaufmann S.H., and McMichael A.J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat Med 11 (2005) S33-44
9. Lewinsohn D.M., Lewinsohn D.A., and Grotzke J.E. TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease. Semin Respir Infect 18 (2003) 320-338
10. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
11. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., Weichold F.F., Hoft D.F., Parida S.K., and Fruth U.J. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5 (2008) e145. This study compares the strengths and weaknesses of various immunoassays used to measure T cell mediated responses to Mtb antigens and provides recommendations for a harmonized assay for use in human clinical trials of new TB vaccines.
12. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 15 (2007) 7-13
13. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457 (2009) 87-91
14. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 (2009) 293-299
15. Ly L.H., Jeevan A., and McMurray D.N. Neutralization of TNFalpha alters inflammation in guinea pig tuberculous pleuritis. Microbes Infect (2009) 10.1016/j.micinf.2009.04.015 Epub
16. Clark S., Cross M.L., Nadian A., Vipond J., Court P., Williams A., Hewinson R.G., Aldwell F.E., and Chambers M.A. Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis. Infect Immun 76 (2008) 3771-3776
17. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., Sadoff J., Hanekom W., Geiter L., and Hussey G. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 (2008) a2052
18. Kemp E.B., Belshe R.B., and Hoft D.F. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis 174 (1996) 113-119
19. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., Ambrozak D.R., Precopio M.L., Scheinberg P., Alder N.C., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37 (2007) 3089-3100. These data from a human clinical study illustrate the effectiveness of the booster TB vaccine vectored by vaccinia, MVA85A, to induce a significant polyfunctional CD4+ T cell response specific for the Mtb antigen 85A when the vaccine is used in individuals previously immunized with a BCG vaccine.
20. Sorensen A.L., Nagai S., Houen G., Andersen P., and Andersen A.B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63 (1995) 1710-1717
21. Coler R.N., Dillon D.C., Skeiky Y.A., Kahn M., Orme I.M., Lobet Y., Reed S.G., and Alderson M.R. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine 27 (2009) 223-233. This paper describes a novel CD4+ T cell expression screening method to identify immunodominant T cell antigens in PPD+ donors. The TB antigen, Mtb9.8, was recognized by multiple individuals and then tested in animal models for TB where it was shown to be a viable new vaccine candidate.
22. Frieder M., and Lewinsohn D.M. T-Cell epitope mapping in Mycobacterium tuberculosis using pepmixes created by micro-scale SPOT- synthesis. Methods Mol Biol 524 (2009) 369-382. This manuscript describes in detail the novel high-throughput system developed by the investigators for using peptide libraries to identify immunodominant antigens and T cell epitopes in subjects infected with M. tuberculosis.
23. Bertholet S., Ireton G.C., Kahn M., Guderian J., Mohamath R., Stride N., Laughlin E.M., Baldwin S.L., Vedvick T.S., Coler R.N., et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 181 (2008) 7948-7957
24. Zvi A., Ariel N., Fulkerson J., Sadoff J.C., and Shafferman A. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics 1 (2008) 18
25. D'Souza S., Rosseels V., Romano M., Tanghe A., Denis O., Jurion F., Castiglione N., Vanonckelen A., Palfliet K., and Huygen K. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71 (2003) 483-493
26. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97 (2000) 13853-13858
27. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., Fletcher H.A., and Hill A.V. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
28. Skjot R.L., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., and Andersen P. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68 (2000) 214-220
29. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 (2001) 2773-2778
30. Brennan M.J., and Delogu G. The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol 10 (2002) 246-249
31. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., Campos-Neto A., Lobet Y., Dalemans W., Orme I.M., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
32. Parra M., Cadieux N., Pickett T., Dheenadhayalan V., and Brennan M.J. A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen. Infect Immun 74 (2006) 786-789
33. Menozzi F.D., Rouse J.H., Alavi M., Laude-Sharp M., Muller J., Bischoff R., Brennan M.J., and Locht C. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184 (1996) 993-1001
34. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., and Menozzi F.D. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
35. Parra M., Pickett T., Delogu G., Dheenadhayalan V., Debrie A.S., Locht C., and Brennan M.J. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72 (2004) 6799-6805
36. Temmerman S., Pethe K., Parra M., Alonso S., Rouanet C., Pickett T., Drowart A., Debrie A.S., Delogu G., Menozzi F.D., et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10 (2004) 935-941
37. van der Wel N., Hava D., Houben D., Fluitsma D., van Zon M., Pierson J., Brenner M., and Peters P.J. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129 (2007) 1287-1298
38. Moody D.B., Ulrichs T., Muhlecker W., Young D.C., Gurcha S.S., Grant E., Rosat J.P., Brenner M.B., Costello C.E., Besra G.S., et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404 (2000) 884-888
39. Glatman-Freedman A., and Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 11 (1998) 514-532
40. Kallenius G., Pawlowski A., Hamasur B., and Svenson S.B. Mycobacterial glycoconjugates as vaccine candidates against tuberculosis. Trends Microbiol 16 (2008) 456-462
41. Elvang T., Christensen J.P., Billeskov R., Thi Kim Thanh Hoang T., Holst P., Thomsen A.R., Andersen P., and Dietrich J. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4 (2009) e5139
42. Reed S.G., Coler R.N., Dalemans W., Tan E.V., DeLa Cruz E.C., Basaraba R.J., Orme I.M., Skeiky Y.A., Alderson M.R., Cowgill K.D., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 106 (2009) 2301-2306
43. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., Vogels R., Skeiky Y.A., Hone D.M., Sadoff J.C., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75 (2007) 4105-4115
44. Wong Y.L., Sampson S., Germishuizen W.A., Goonesekera S., Caponetti G., Sadoff J., Bloom B.R., and Edwards D. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A 104 (2007) 2591-2595
45. Garcia-Contreras L., Wong Y.L., Muttil P., Padilla D., Sadoff J., Derousse J., Germishuizen W.A., Goonesekera S., Elbert K., Bloom B.R., et al. Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 105 (2008) 4656-4660
46. Ramachandra L., Simmons D., and Harding C.V. MHC molecules and microbial antigen processing in phagosomes. Curr Opin Immunol 21 (2009) 98-104
47. Flynn J.L., and Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 15 (2003) 450-455
48. Gan H., Lee J., Ren F., Chen M., Kornfeld H., and Remold H.G. Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol 9 (2008) 1189-1197
49. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., Bandermann S., Smith D., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
50. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 (2008) 247-258. This is a notable review highlighting the importance of measuring polyfunctional responses in T cells and the implications for both effector and memory T cell populations.
51. Chen C.Y., Huang D., Wang R.C., Shen L., Zeng G., Yao S., Shen Y., Halliday L., Fortman J., McAllister M., et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 5 (2009) e1000392. This study in a non-human primate model of TB demonstrates that CD8+ T cell depletion of Rhesus macaques results in reduced ability of the animals to control the resulting disease after challenge with Mtb, providing evidence that CD8+ T cells play an important role in protecting against TB.
52. Baldwin S.L., D'Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., Ulmer J.B., Huygen K., McMurray D.M., and Orme I.M. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 (1998) 2951-2959
53. Chambers M.A., Williams A., Gavier-Widen D., Whelan A., Hughes C., Hall G., Lever M.S., Marsh P.D., and Hewinson R.G. A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet Microbiol 80 (2001) 213-226
54. Fletcher H.A., Keyser A., Bowmaker M., Sayles P.C., Kaplan G., Hussey G., Hill A.V., and Hanekom W.A. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC Med Genomics 2 (2009) 10
55. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993) 2249-2254
56. Hoft D.F., Worku S., Kampmann B., Whalen C.C., Ellner J.J., Hirsch C.S., Brown R.B., Larkin R., Li Q., Yun H., et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 186 (2002) 1448-1457
57. Fine P.E. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11 Suppl. 2 (1989) S353-S359
58. McShane H., and Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7 (2005) 962-967
59. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., Weichold F., Geiter L., Sadoff J.C., and Horwitz M.A. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198 (2008) 1491-1501. This study provides the promising results from the first human clinical trial of a new live recombinant BCG vaccine.
60. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., and Kaufmann S.H. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 95 (1998) 5299-5304
61. Magalhaes I., Sizemore D.R., Ahmed R.K., Mueller S., Wehlin L., Scanga C., Weichold F., Schirru G., Pau M.G., Goudsmit J., et al. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 3 (2008) e3790
62. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., Dolganov G., Efron B., Butcher P.D., Nathan C., et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198 (2003) 693-704
63. Schnappinger D., Schoolnik G.K., and Ehrt S. Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. Microbes Infect 8 (2006) 1132-1140
64. Cardona P.J., Asensio J.G., Arbues A., Otal I., Lafoz C., Gil O., Caceres N., Ausina V., Gicquel B., and Martin C. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 27 (2009) 2499-2505
65. Derrick S.C., Evering T.H., Sambandamurthy V.K., Jalapathy K.V., Hsu T., Chen B., Chen M., Russell R.G., Junqueira-Kipnis A.P., Orme I.M., et al. Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology 120 (2007) 192-206
66. Sambandamurthy V.K., Derrick S.C., Hsu T., Chen B., Larsen M.H., Jalapathy K.V., Chen M., Kim J., Porcelli S.A., Chan J., et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24 (2006) 6309-6320
67. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., van der Werff N.M., Kersbergen A., Ottenhoff T.H., Heidt P.J., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4 (2009) e5264. This study provides evidence from a non-human primate model of TB that the new modified vaccinia vectored, MVA85A, vaccine can function as a booster for a BCG vaccine prime to improve protection against an Mtb challenge in Rhesus macaques. It is also the first study to show that a live attenuated phoP deficient Mtb vaccine is well tolerated and affords protection in a non-human primate model.
68. Chan J., and Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol 110 (2004) 2-12
69. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., Lang T., Veldsman A., Hatherill M., Merwe L., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198 (2008) 544-552
70. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., Lambert P.H., and Siegrist C.A. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS ONE 3 (2008) e3683
71. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 73 (2005) 4676-4683